Salarius Pharmaceuticals

PriceSalarius Pharmaceuticals

SLRX

Salarius Pharmaceuticals Inc is a clinical-stage biopharmaceutical company focused on developing effective treatments for cancers with high, unmet medical needs. The company has focused on two classes of drugs that address gene dysregulation: targeted protein inhibitors and targeted protein degradation. Its Pipeline includes seclidemstat (SP-2577), a small molecular inhibitor, and SP-3164, a small molecular protein degrader.

Historical stock price chart and annual return over the past years

-99%

5 years

% Total

SLRX
-65%

5 years

Annual Return

SLRX